Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-01-24T22:59:16.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Cerebellar Atrophy in Epileptic Patients

Published online by Cambridge University Press:  18 September 2015

M.I. Botez ,
Ezzedine Attig  and
Jean Lorrain Vézina
M.I. Botez*
Affiliation:
Neurology Service and Department of Radiology, Hôtel-Dieu de Montréal and Centre Hospitalier Rouyn-Noranda, Québec, Canada
Ezzedine Attig
Affiliation:
Neurology Service and Department of Radiology, Hôtel-Dieu de Montréal and Centre Hospitalier Rouyn-Noranda, Québec, Canada
Jean Lorrain Vézina
Affiliation:
Neurology Service and Department of Radiology, Hôtel-Dieu de Montréal and Centre Hospitalier Rouyn-Noranda, Québec, Canada
*
Head, Neurology Service, Hôtel-Dieu de Montréal, 3840 St-Urbain, Montreal, Québec, Canada H2W 1T8
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

High-resolution CT scans of the brain and posterior fossa were performed on 106 phenytoin (PHT)- treated epileptics, 28 de novo epileptics and 43 control subjects. A higher incidence of cerebellar and brainstem (CBS) atrophy was observed in chronic PHT- or PHT+ phenobarbital-treated epileptics compared to the two other groups. Some control subjects and de novo epileptics presented mild CBS atrophy, whereas moderate to severe atrophy was noted exclusively in chronically-treated patients. In attempting to delineate the etiology of CBS atrophy, epileptic patients were divided in three groups: 55 subjects with normal CT scans, 30 with both cerebral and CBS atrophy, and 49 with pure CBS atrophy. Their ages, length of illness, number of generalized seizures, number of other seizures, and amount of PHT received during their lifetime were assessed. Statistical analysis revealed that posterior fossa atrophy in epileptics was significantly correlated with both the length of the illness and the amount of PHT ingested during the patient's lifetime. The number of seizures appears to not be related to CBS atrophy.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 15 , Issue 3 , August 1988 , pp. 299 - 303
Copyright
Copyright © Canadian Neurological Sciences Federation 1988

References

REFERENCES

1.Hofmann, WW.Cerebellar lesions after parenteral dilanlin administration. Neurology 1958; 8: 210–14.CrossRefGoogle ScholarPubMed
2.Utterback, RA.Parenchymatous cerebellar degeneration complicating diphenylhydantoin therapy. Arch Neurol Psychiatry 1958; 80: 180–1.Google Scholar
3.Roger, J, Soulayrol, R.A propos des accidents neurologiques du traitement de l’épilepsie par les hydantoines. Rev Neurol (Paris) 1959; 100: 783–85.Google Scholar
4.Haberland, C.Cerebellar degeneration with clinical manifestations in chronic epileptic patients. Psychiatr Neurol (Basel) 1962; 143: 29–44.CrossRefGoogle ScholarPubMed
5.Kokenge, R, Kutt, H, McDowell, F.Neurological sequelae following Dilantin overdose in a patient and in experimental animals. Neurology (Minneap) 1965; 15: 823–9.CrossRefGoogle Scholar
6.Selhorst, JB, Kaufman, B, Horwitz, SJ.Diphenylhydantoin-induced cerebellar degeneration. Arch Neurol 1972; 27: 453–5.CrossRefGoogle ScholarPubMed
7.Ghatak, NR, Sarnoso, RA, McKinney, WM.Cerebellar degeneration following long-term phenytoin therapy. Neurology (Minneap) 1976; 26: 818–20.CrossRefGoogle ScholarPubMed
8.Salcman, M, Defendini, R, Correli, J, et al. Neuropathological changes in cerebellar biopsies of epileptic patients. Ann Neurol 1978; 3: 10–19.CrossRefGoogle ScholarPubMed
9.McLain, LW, Martin, JT, Allen, JH.Cerebellar degeneration due to chronic phenytoin therapy. Ann Neurol 1980; 7: 18–23.CrossRefGoogle ScholarPubMed
10.Koller, WC, Glatt, SL, Fox, JH.Phenytoin-induced cerebellar degeneration. Ann Neurol 1980; 8: 203–4.CrossRefGoogle ScholarPubMed
11.Breiden-Arends, C, Gullotta, F.Diphenylhydantoin, Epilepsie, Kleinhirnatrophie-Histologische und elektronenmikroskopische Untersuchugen. Fortschr Neurol Psychiatr 1981; 49: 406–14.CrossRefGoogle Scholar
12.livainen, M, Viukari, M, Helle, E-P.Cerebellar atrophy in phenytointreated mentally retarded epileptics. Epilepsia 1977; 18: 375–85.Google Scholar
13.Tsukamoto, Y, Kondo, K, Yoshiota, M.Antiepileptic drugs and cerebellar atrophy. Acta Neurol Scand (Suppl. 79) 1980; 62: 89.Google Scholar
14.Bittencourt, PRM.Cerebral and cerebellar atrophy in patients with severe epilepsy: a preliminary report. In: Oxley, J, Janz, D, Meinardi, H, eds. Antiepileptic Therapy: Chronic Toxicity of Antiepileptic Drugs, New York: Raven Press, 1983: 237–45.Google Scholar
15.Dam, M.Chronic toxicity of antiepileptic drugs with respect to cerebellar and motor function. In: Oxley, J.Janz, D, Meinardi, H, eds. Chronic Toxicity of Antiepileptic Drugs, New York: Raven Press, 1983: 223–28.Google Scholar
16.Botez, MI, Gravel, J.Attig, E, et al. Reversible chronic cerebellar ataxia following phenytoin intoxication. The possible role of the cerebellum in cognitive thought. Neurology (Cleveland) 1985: 35: 1152–57.CrossRefGoogle Scholar
17.Spielmeyer, W.Uber einige Beziehungen zwischen Ganglienzelleveranderungen und gliosen Erscheinungen, besonders am Kleinhirn. Z ges Neurol Psychiatr 1920; 54: 1–38.CrossRefGoogle Scholar
18.Merritt, HH, Putnam, TJ.Sodium diphenylhydantoinate in the treatment of convulsive disorders. J Am Med Assoc 1938; 111: 1068–73.CrossRefGoogle Scholar
19.Ballenger, CE, Lucke, JF, King, DW, et al. Cerebellar atrophy in epilepsy and headache: lack of relationship to phenytoin. Neurology (NY) 1982; 32: 910–12.CrossRefGoogle ScholarPubMed
20.Mattson, RH, Cramer, JA, Escueta, AVD, et al. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology (Cleveland) 1983; 33 (Suppl. 1): 14–25.CrossRefGoogle ScholarPubMed
21.Huckman, MS, Fox, JH, Topel, JL.The validity of criteria for the evaluation of cerebral atrophy by computed tomography. Radiology 1975; 116: 85–92.CrossRefGoogle ScholarPubMed
22.Hahn, FJY, Kwan, R.Frontal ventricular dimensions on normal computed tomographyq. Am J Roentgenol 1976; 126: 593–6.CrossRefGoogle Scholar
23.Koller, WC, Glatt, SL, Perlik, S, et al. Cerebellar atrophy demonstrated by computed tomography. Neurology (NY) 1981; 31: 405–12.CrossRefGoogle ScholarPubMed
24.Kirk, RE.Experimental design: procedures for the Behavioral Sciences. Wadsworth, Belmont, 1968.Google Scholar
25.Winer, BJ.Statistical principles in experimental design. McGraw-Hill, New York, 1971.Google Scholar
26.Ferguson, GA.Statistical analysis in psychology and education. New York: McGraw-Hill, 1971.Google Scholar
27.Dam, M.Number of Purkinje cells in patients with grand mal epilepsy treated with diphenylhydantoin. Epilepsia 1970; 11: 313–320.Google ScholarPubMed
28.Marguerison, JH, Corsellis, JAN.Epilepsy and the temporal lobes. Brain 1966; 89: 499–533.CrossRefGoogle Scholar
29.Meldrum, BS, Horton, RW, Brierley, JB.Epileptic brain damage in adolescent baboons following seizures induced by allyglycine. Brain 1974; 97: 407–18.CrossRefGoogle Scholar
30.Reynolds, EH.Discussion: motor and cerebellar disorders. In Oxley, J, Janz, D, Meinardi, H, eds., Chronic Toxicity of Antiepileptic Drugs, New York: Raven Press, 1983: 249.Google Scholar